Swiss National Bank Boosts Stake in The Cooper Companies, Inc. $COO

Swiss National Bank grew its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 7.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 605,400 shares of the medical device company’s stock after acquiring an additional 42,500 shares during the quarter. Swiss National Bank owned about 0.30% of Cooper Companies worth $43,080,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Zions Bancorporation National Association UT bought a new stake in shares of Cooper Companies in the 1st quarter valued at about $33,000. J.Safra Asset Management Corp grew its stake in Cooper Companies by 204.8% during the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock worth $36,000 after buying an additional 340 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in Cooper Companies during the 1st quarter valued at about $40,000. Assetmark Inc. increased its position in Cooper Companies by 357.8% during the 2nd quarter. Assetmark Inc. now owns 618 shares of the medical device company’s stock valued at $44,000 after buying an additional 483 shares in the last quarter. Finally, Allworth Financial LP raised its stake in Cooper Companies by 36.6% in the second quarter. Allworth Financial LP now owns 959 shares of the medical device company’s stock valued at $68,000 after buying an additional 257 shares during the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on COO shares. Morgan Stanley set a $76.00 price target on Cooper Companies and gave the stock an “equal weight” rating in a research note on Thursday, August 28th. Stifel Nicolaus dropped their target price on shares of Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, August 28th. Weiss Ratings restated a “sell (d+)” rating on shares of Cooper Companies in a research note on Wednesday, November 19th. Wells Fargo & Company reiterated an “equal weight” rating and set a $72.00 price objective on shares of Cooper Companies in a research note on Thursday, November 13th. Finally, Barclays assumed coverage on Cooper Companies in a research report on Monday, October 13th. They issued an “overweight” rating and a $85.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Cooper Companies has a consensus rating of “Moderate Buy” and a consensus price target of $84.77.

Insider Transactions at Cooper Companies

In other news, CEO Albert G. White III acquired 10,000 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were acquired at an average price of $68.39 per share, with a total value of $683,900.00. Following the purchase, the chief executive officer directly owned 226,151 shares of the company’s stock, valued at $15,466,466.89. This trade represents a 4.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of the business’s stock in a transaction on Monday, September 29th. The stock was purchased at an average cost of $68.39 per share, with a total value of $136,780.00. Following the acquisition, the director directly owned 5,777 shares of the company’s stock, valued at $395,089.03. This represents a 52.95% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 17,975 shares of company stock valued at $1,216,346. 1.98% of the stock is owned by insiders.

Cooper Companies Stock Up 0.7%

NASDAQ:COO opened at $76.01 on Tuesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The company’s fifty day moving average price is $70.36 and its 200-day moving average price is $71.87. The Cooper Companies, Inc. has a 1-year low of $61.78 and a 1-year high of $106.63. The firm has a market capitalization of $15.11 billion, a P/E ratio of 37.44, a PEG ratio of 1.83 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.07 by $0.03. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. The firm’s revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies declared that its board has authorized a share repurchase program on Wednesday, September 17th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical device company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.